Filtros de búsqueda

Lista de obras de Roman Hajek

1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens

artículo científico publicado en 2012

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

artículo científico publicado en 2017

A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2019

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

artículo científico publicado en 2018

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

artículo científico publicado en 2016

Activity of aldehyde dehydrogenase in B-cell and plasma cell subsets of monoclonal gammopathy patients and healthy donors.

artículo científico publicado en 2016

Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.

artículo científico publicado en 2012

Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.

artículo científico publicado en 2017

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

artículo científico publicado en 2018

Association of aneuploidy category with centrosome amplification in multiple myeloma

artículo científico publicado en 2011

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

artículo científico publicado en 2016

Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies.

artículo científico publicado en 2017

Bone marrow plasma cell separation - validation of separation algorithm.

artículo científico publicado en 2012

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

artículo científico publicado en 2015

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma

artículo científico publicado en 2016

Capillary immunotyping electrophoresis and high resolution two-dimensional electrophoresis for the detection of mu-heavy chain disease.

artículo científico publicado en 2007

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

artículo científico publicado en 2017

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

scientific article published on 28 February 2019

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

artículo científico publicado en 2016

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

article

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

artículo científico publicado en 2017

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.

artículo científico publicado en 2016

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment

artículo científico publicado en 2017

Centrosome amplification and clonal evolution in multiple myeloma: Short review.

artículo científico publicado en 2015

Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma.

artículo científico publicado en 2010

Centrosome associated genes pattern for risk sub-stratification in multiple myeloma.

artículo científico publicado en 2016

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

artículo científico publicado en 2015

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

scientific article published on 22 August 2019

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma

artículo científico publicado en 2015

Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance

artículo científico publicado en 2013

Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma

artículo científico publicado en 2013

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project

artículo científico publicado en 2018

Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia

artículo científico publicado en 2015

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

artículo científico publicado en 2012

Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.

artículo científico publicado en 2012

Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial

artículo científico publicado en 2011

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

artículo científico publicado en 2011

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.

scientific article published on August 2010

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

article

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

artículo científico publicado en 2015

Current applications of multiparameter flow cytometry in plasma cell disorders

artículo científico publicado en 2017

Cytogenetics in multiple myeloma patients progressing into extramedullary disease.

artículo científico publicado en 2015

Cytokine analysis in a patient with relapsing Kikuchi-Fujimoto disease

artículo científico publicado en 2011

Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.

artículo científico publicado en 2000

Deregulated expression of long non-coding RNA UCA1 in multiple myeloma

artículo científico publicado en 2017

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

artículo científico publicado en 2012

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients.

artículo científico publicado en 2014

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma

artículo científico publicado en 2019

Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview.

artículo científico publicado en 2016

Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients

artículo científico publicado en 2019

Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.

artículo científico publicado en 2017

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.

artículo científico publicado en 2012

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

artículo científico publicado en 2017

Epigenetics of multiple myeloma after treatment with cytostatics and gamma radiation.

artículo científico publicado en 2009

European Myeloma Network guidelines for the management of multiple myeloma-related complications

artículo científico publicado en 2015

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

artículo científico publicado en 2010

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

artículo científico publicado en 2018

European perspective on multiple myeloma treatment strategies in 2014

artículo científico publicado en 2014

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma

artículo científico publicado en 2017

Expression of RAN, ZHX-2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors.

artículo científico publicado en 2010

Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data

artículo científico publicado en 2015

Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial

artículo científico publicado en 2013

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

artículo científico publicado en 2016

Flow cytometry in immunoglobulin light chain amyloidosis: Short review.

artículo científico

Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2020

artículo científico publicado en 2020

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

artículo científico publicado en 2018

Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.

artículo científico publicado en 2012

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

artículo científico publicado en 2010

Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib

artículo científico publicado en 2013

Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations

artículo científico publicado en 2003

Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.

artículo científico publicado en 2014

Genomewide association study on monoclonal gammopathy of unknown significance (MGUS).

artículo científico publicado en 2017

Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance

artículo científico publicado en 2016

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

artículo científico publicado en 2015

Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

artículo científico publicado en 2016

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

article

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma

artículo científico publicado en 2017

High-risk multiple myeloma: different definitions, different outcomes?

artículo científico

Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model

scientific article published on 12 March 2020

IgM myeloma: A multicenter retrospective study of 134 patients

artículo científico publicado en 2017

Immunomodulatory drugs in AL amyloidosis

artículo científico publicado en 2016

Immunoparesis in MGUS - Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories

artículo científico publicado en 2015

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

scientific article published on 05 August 2016

Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH.

artículo científico publicado en 2014

Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.

artículo científico publicado en 2012

Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma

artículo científico publicado en 2012

Interdigitating dendritic cell sarcoma of the leg.

artículo científico publicado en 2009

Interleukin-2 Activation of Haematopoietic Stem Cells

artículo científico publicado en 2002

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

artículo científico publicado en 2014

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

artículo científico publicado en 2008

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

artículo científico publicado en 2009

International Myeloma Working Group recommendations for global myeloma care

artículo científico publicado en 2013

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

artículo científico publicado en 2020

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

scientific article published on 25 June 2009

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

scientific article published on 09 November 2018

Lenalidomide proved effective in multisystem Langerhans cell histiocytosis

scientific article published on 21 November 2011

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.

artículo científico

Lenalidomide: a new treatment option for Castleman disease

artículo científico publicado en 2011

Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?

artículo científico publicado en 2019

Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response

artículo científico publicado en 2009

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

artículo científico publicado en 2010

Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.

artículo científico publicado en 2009

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

artículo científico publicado en 2018

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2017

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

scientific article published on 22 May 2020

Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma.

artículo científico publicado en 2011

Mechanism of immunomodulatory drugs in multiple myeloma.

artículo científico publicado en 2012

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

artículo científico publicado en 2015

Molecular heterogeneity and centrosome-associated genes in multiple myeloma.

artículo científico publicado en 2013

Monoclonal antibodies - A new era in the treatment of multiple myeloma.

artículo científico

Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits

scientific article published on 18 February 2020

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

artículo científico publicado en 2010

Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment

scientific article published on 04 September 2007

Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.

artículo científico

Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen

artículo científico publicado en 2011

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

article

MyelomA Genetics International Consortium

artículo científico

Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.

artículo científico publicado en 2013

Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation

scientific article published on 01 January 2010

Nestin expression throughout multistep pathogenesis of multiple myeloma

artículo científico publicado en 2013

Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing.

artículo científico publicado en 2018

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review

artículo científico publicado en 2020

Nuclear topography of the 1q21 genomic region and Mcl-1 protein levels associated with pathophysiology of multiple myeloma.

artículo científico publicado en 2009

Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting.

artículo científico publicado en 2010

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

scientific article published on 04 February 2011

Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy

scientific article published on 01 January 2005

PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.

artículo científico publicado en 2017

PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

artículo científico publicado en 2016

Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance

artículo científico publicado en 2009

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

artículo científico publicado en 2012

Plasma cell leukemia: from biology to treatment

artículo científico

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

artículo científico publicado en 2013

Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma

artículo científico publicado en 2010

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.

artículo científico publicado en 2005

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

artículo científico publicado en 2018

Prognostic significance of morphological assessment of plasma cells in multiple myeloma

artículo científico publicado en 2011

Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma

artículo científico publicado en 2014

Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.

artículo científico publicado en 2016

Proteomic Analysis in Multiple Myeloma Research ⬇️

artículo científico publicado el 1 de enero de 2011

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

scientific article published on 01 April 2020

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

scientific article published on 09 March 2020

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

artículo científico publicado en 2020

Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.

scientific article published on March 2010

Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma.

artículo científico publicado en 2009

Second autologous transplantation for multiple myeloma patients relapsing after the first autograft -- a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma

scientific article published on 01 June 2004

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

artículo científico publicado en 2014

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

artículo científico publicado en 2018

Sepsis and septic shock. II. Treatment.

artículo científico publicado en 1995

Serum miR-29a as a marker of multiple myeloma.

artículo científico publicado en 2012

Shared structural features of the 9aaTAD family in complex with CBP.

artículo científico publicado en 2015

Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma

artículo científico publicado en 2011

Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t[11;14]

scientific article published on 25 November 2018

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.

artículo científico publicado en 2013

Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients

scientific article published on 26 March 2011

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

artículo científico publicado en 2012

TGF-β - an excellent servant but a bad master

artículo científico publicado en 2012

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

artículo científico publicado en 2010

The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma

artículo científico publicado en 2018

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

artículo científico publicado en 2014

The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets

artículo científico publicado en 2018

The miR-29 family in hematological malignancies.

artículo científico publicado en 2014

The problems of proteinuria measurement in urine with presence of Bence Jones protein ⬇️

artículo científico publicado el 1 de febrero de 2011

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

artículo científico

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma

artículo científico publicado en 2017

The start of a new wave: Developments in proteasome inhibition in multiple myeloma.

artículo científico publicado en 2018

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response

artículo científico publicado en 2018

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review

scientific article published on 01 July 2018

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

artículo científico publicado en 2016

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma

artículo científico publicado en 2018

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

artículo científico publicado en 2018

Venetoclax: A new wave in hematooncology.

artículo científico publicado en 2018

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

artículo científico publicado en 2013

Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection.

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda